{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Gao X"],"funding":["the National Key Research and Development Program of China"],"pagination":["25"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12913845"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["13(1)"],"pubmed_abstract":["Radiation enteritis is a common complication in patients undergoing abdominal radiotherapy. Current management strategies face significant limitations: clinical agents like amifostine are hindered by systemic side effects and demanding administration; direct supplementation with radioprotective metabolites such as propionate suffers from low bioavailability and transient action; and conventional probiotics lack targeted therapeutic output. To address these challenges, we engineered Escherichia coli Nissle 1917 to function as a living therapeutic that continuously produces and delivers propionate directly in the gut. This propionate-engineered probiotic achieved a production yield of 181.33 ± 4.27 mg/L in vitro. In a mouse model of abdominal irradiation, this engineered bacterium alleviated"],"journal":["Bioresources and bioprocessing"],"pubmed_title":["Propionate-engineered probiotics reduce radiation-induced intestinal damage."],"pmcid":["PMC12913845"],"funding_grant_id":["2024YFA0918500"],"pubmed_authors":["Wu J","Zhu Z","Guo Y","Lu X","Huang H","Ji K","Liu Q","Zhao Z","Wang L","Wang P","Kang G","Gao M","Wang Q","Jia X","Gao X"],"additional_accession":[]},"is_claimable":false,"name":"Propionate-engineered probiotics reduce radiation-induced intestinal damage.","description":"Radiation enteritis is a common complication in patients undergoing abdominal radiotherapy. Current management strategies face significant limitations: clinical agents like amifostine are hindered by systemic side effects and demanding administration; direct supplementation with radioprotective metabolites such as propionate suffers from low bioavailability and transient action; and conventional probiotics lack targeted therapeutic output. To address these challenges, we engineered Escherichia coli Nissle 1917 to function as a living therapeutic that continuously produces and delivers propionate directly in the gut. This propionate-engineered probiotic achieved a production yield of 181.33 ± 4.27 mg/L in vitro. In a mouse model of abdominal irradiation, this engineered bacterium alleviated","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Feb","modification":"2026-07-16T06:58:14.118Z","creation":"2026-07-09T13:10:59.852Z"},"accession":"S-EPMC12913845","cross_references":{"pubmed":["41701295"],"doi":["10.1186/s40643-026-01020-9"]}}